Mercilon (Desogestrel, Ethinylestradiol)

• Mercilon, a combined oral contraceptive, is used within the hormonal birth‑control pathway for several reproductive health indications.
• Contraception: prevention of pregnancy in women of child‑bearing potential.
• Menstrual cycle regulation: reduction of irregular bleeding and dysmenorrhea.
• Acne improvement: decrease in androgen‑related facial acne.

• Desogestrel/Ethinylestradiol exerts its effect by inhibiting the hypothalamic‑pituitary‑gonadal axis, suppressing the mid‑cycle surge of luteinizing hormone and follicle‑stimulating hormone, which prevents ovulation. Ethinylestradiol also stabilises the endometrial lining and increases cervical mucus viscosity, creating an environment hostile to sperm penetration and implantation.

Mercilon may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects

• Nausea or gastrointestinal discomfort.
• Breast tenderness or enlargement.
• Headache or migraine.
• Weight gain or fluid retention.
• Mood changes or irritability.
• Breakthrough or spotting bleeding.

Serious or Rare Side Effects

• Venous thromboembolism (deep vein thrombosis, pulmonary embolism).
• Arterial thrombosis (stroke, myocardial infarction).
• Hypertension or severe blood pressure elevation.
• Liver dysfunction or cholestatic jaundice.
• Severe allergic reactions (anaphylaxis, angioedema).
• Visual disturbances or ocular migraines.

• Before prescribing Mercilon, clinicians should consider several safety aspects.
• Assess cardiovascular risk: evaluate personal or family history of thrombosis.
• Screen for smoking status: avoid use in women over 35 who smoke.
• Consider liver function: contraindicated in active liver disease.
• Review medication list: avoid concomitant use with strong enzyme‑inducing drugs.
• Monitor blood pressure: watch for new or worsening hypertension.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Mercilon can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced contraceptive efficacy.
• Anticoagulants (e.g., warfarin): altered anticoagulant effect.
• Protease inhibitor antiretrovirals: possible increase in hormone levels.
• St. John’s wort: decreased contraceptive effectiveness.
• Azole antifungals (e.g., ketoconazole): may raise hormone concentrations.

Moderate Interactions (Monitor Closely)

• SSRIs (selective serotonin reuptake inhibitors): may increase mood‑related side effects.
• Beta‑blockers: potential additive effect on blood pressure control.
• Moderate enzyme‑inducing anticonvulsants (e.g., phenobarbital): may lower efficacy.
• Diuretics: possible electrolyte disturbances.
• Herbal supplements such as ginseng: monitor for menstrual changes.